Valion Bio (VBIO) Return on Capital Employed (2022 - 2026)
Valion Bio (VBIO) posted quarterly Return on Capital Employed of 32.02% for Q4 2025, up 16813.0% year-over-year from N/an in Q4 2024, and up 79.55% quarter-over-quarter from 156.56% in Q3 2025.
Valion Bio (VBIO) Return on Capital Employed (2022 - 2026) Analysis & Trends
Valion Bio's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 32.02% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 16813.0% year-over-year to 32.02%; the TTM figure through Dec 2025 stood at 32.02% (up 16813.0% YoY), while the FY2025 annual figure was 0.19%, up 15278.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 32.02%, up from 156.56% in the prior quarter.
- The five-year high for Return on Capital Employed was 32.02% in Q4 2025, with the low at 235.64% in Q1 2024.
- The 4-year median for Return on Capital Employed is 186.65% (2024), against an average of 164.77%.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed sank 14954 bps in 2023, then jumped 16813 bps in 2025.
- Valion Bio's Return on Capital Employed stood at 195.58% in 2022, then advanced by 10 bps to 176.14% in 2023, then decreased by 14 bps to 200.14% in 2024, then jumped by 84 bps to 32.02% in 2025.
- Business Quant data shows VBIO's Return on Capital Employed at 32.02% in Q4 2025, 156.56% in Q3 2025, and 191.3% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | -15.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.14% |
| Dec 31, 2025 | -32.02% |
| Sep 30, 2025 | -156.56% |
| Jun 30, 2025 | -191.30% |
| Mar 31, 2025 | -222.89% |
| Dec 31, 2024 | -200.14% |
| Sep 30, 2024 | -182.00% |
| Jun 30, 2024 | -196.05% |
| Mar 31, 2024 | -235.64% |
| Dec 31, 2023 | -176.14% |
| Sep 30, 2023 | -171.97% |
| Jun 30, 2023 | -193.69% |
| Mar 31, 2023 | -202.93% |
| Dec 31, 2022 | -195.58% |
| Sep 30, 2022 | -133.46% |
| Jun 30, 2022 | -92.60% |
| Mar 31, 2022 | -53.39% |